Attached files
| file | filename |
|---|---|
| 8-K - 8-K - BRISTOL MYERS SQUIBB CO | q22018earningsrelease8-k.htm |
| EX-99.2 - CERTAIN SUPPLEMENTAL INFORMATION - BRISTOL MYERS SQUIBB CO | q22018ex992.htm |
Exhibit 99.1
Bristol-Myers Squibb Reports Second Quarter Financial Results
• | Increases Second Quarter Revenues 11% to $5.7 Billion |
• | Posts Second Quarter GAAP EPS of $0.23 and Non-GAAP EPS of $1.01 |
• | Achieves Significant Regulatory Milestones in Oncology |
• | Presents Important New Data on Immuno-Oncology Portfolio at ASCO |
• | Updates 2018 GAAP and Non-GAAP EPS Guidance |
(NEW YORK, July 26, 2018) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2018, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab), and important regulatory progress in the company’s Immuno-Oncology portfolio.
“We had a very good second quarter where we delivered strong performance for Eliquis and Opdivo, and achieved important regulatory and data milestones supporting our Immuno-Oncology portfolio,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “Looking forward, we are focused on robust commercial execution and the evolution of our diversified pipeline to deliver transformational medicines to the patients we serve.”
Second Quarter | ||||||||||
$ amounts in millions, except per share amounts | ||||||||||
2018 | 2017 | Change | ||||||||
Total Revenues | $ | 5,704 | $ | 5,144 | 11 | % | ||||
GAAP Diluted EPS | 0.23 | 0.56 | (59 | )% | ||||||
Non-GAAP Diluted EPS | 1.01 | 0.74 | 36 | % | ||||||
1
SECOND QUARTER FINANCIAL RESULTS
• | Bristol-Myers Squibb posted second quarter 2018 revenues of $5.7 billion, an increase of 11% compared with the same period a year ago. Revenues increased 9% when adjusted for foreign exchange impact. |
• | U.S. revenues increased 13% to $3.2 billion in the quarter compared to the same period a year ago. International revenues increased 9%. When adjusted for foreign exchange impact, international revenues increased 4%. |
• | Gross margin as a percentage of revenue increased from 69.5% to 71.5% in the quarter primarily due to an impairment charge for a manufacturing site in the prior period. |
• | Marketing, selling and administrative expenses decreased 5% to $1.1 billion in the quarter. |
• | Research and development expenses increased 45% to $2.4 billion in the quarter, which includes a $1.1 billion charge resulting from the Nektar collaboration in the second quarter of 2018. |
• | The effective tax rate was 26.1% in the quarter, compared to 28.8% in the second quarter last year. The effective tax rate includes a nondeductible equity investment loss in the second quarter of 2018. |
• | The company reported net earnings attributable to Bristol-Myers Squibb of $373 million, or $0.23 per share, in the second quarter compared to net earnings of $916 million, or $0.56 per share, for the same period in 2017. |
• | The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $1.6 billion, or $1.01 per share, in the second quarter, compared to $1.2 billion, or $0.74 per share, for the same period in 2017. An overview of specified items is provided under the “Use of Non-GAAP Financial Information” section. |
• | Cash, cash equivalents and marketable securities were $8.2 billion, with a net cash position of $805 million, as of June 30, 2018. |
2
SECOND QUARTER PRODUCT AND PIPELINE UPDATE
Product Sales/Business Highlights
Global revenues for the second quarter of 2018, compared to the second quarter of 2017, were driven by:
• | Eliquis, which grew by $474 million or a 40% increase |
• | Opdivo, which grew by $432 million or a 36% increase |
• | Orencia, which grew by 9% |
• | Sprycel, which grew by 6% |
• | Yervoy, which decreased by 2% |
Opdivo
Regulatory
• | In July, the company announced the U.S. Food and Drug Administration (FDA) approved Opdivo plus low-dose Yervoy (injections for intravenous use) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan. |
• | In June, the company announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended expanded approval of the current indications for Opdivo to include the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The CHMP recommendation will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union. |
• | In June, the company announced the FDA accepted its supplemental Biologics License Application for Opdivo plus low-dose Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb). |
• | In June, the China National Drug Administration approved Opdivo for the treatment of locally advanced or metastatic NSCLC after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations. |
• | In May, the EMA validated a type II variation application for the Opdivo plus Yervoy combination for treatment in adult patients with first-line metastatic NSCLC who have TMB ≥10 mut/Mb. |
Clinical
• | In June, at the 2018 American Society of Clinical Oncology, the company announced important new data and analysis from four studies evaluating Opdivo as monotherapy and in combination with Yervoy, chemotherapy or NKTR-214: |
3
◦ | CheckMate -227: Results from a part of the Phase 3 trial evaluating Opdivo plus low-dose Yervoy and Opdivo plus chemotherapy versus chemotherapy in patients with first-line advanced NSCLC with PD-L1 expression <1%, across squamous and non-squamous tumor histologies (Part 1b). (link) |
◦ | CheckMate -238: Results from the Phase 3 trial evaluating Opdivo versus Yervoy in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection. (link) |
◦ | CheckMate -214: Patient-reported outcomes from the Phase 3 trial evaluating Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period in intermediate- and poor-risk patients with advanced renal cell carcinoma. (link) |
◦ | Results from the Phase 1/2 dose-escalation study with Nektar Therapeutics, evaluating the safety, efficacy and biomarker data of NKTR-214 in combination with Opdivo for patients enrolled in the Phase 1 dose-escalation stage of the study and for the first patients consecutively enrolled in select dose expansion cohorts in Phase 2. (link) |
Sprycel
Regulatory
• | In July, the company announced the EC has expanded the indication for Sprycel to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, and to include a powder for oral suspension formulation. |
Empliciti
Clinical
• | In June, the company announced the Phase 2 study evaluating the addition of Empliciti to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma showed a statistically significant and clinically meaningful improvement in progression free survival for patients treated with EPd compared with pomalidomide and dexamethasone alone. (link) |
4
SECOND QUARTER BUSINESS DEVELOPMENT UPDATE
• | In July, the company and Tsinghua University announced a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers. The collaboration brings together the respective scientific expertise and capabilities of both organizations with a focus on validating new targets and generating early drug candidates for clinical development. |
• | In April, the company and Nektar Therapeutics completed the agreement for the development and commercialization of NKTR-214 with Opdivo and Opdivo plus Yervoy, originally announced in February 2018. |
• | In April, the company and Flatiron Health announced a three-year agreement to curate regulatory-grade real-world data for cancer research and real-world evidence generation. |
2018 FINANCIAL GUIDANCE
Bristol-Myers Squibb is decreasing its 2018 GAAP EPS guidance range from $2.70 - $2.80 to $2.68 - $2.78 and increasing its non-GAAP EPS guidance range from $3.35 - $3.45 to $3.55 - $3.65. Both GAAP and non-GAAP guidance assume current exchange rates. Key revised 2018 GAAP and non-GAAP line-item guidance assumptions are:
• | Worldwide revenues increasing in the mid- to high-single digits. |
The financial guidance for 2018 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2018 guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.
Use of Non-GAAP Financial Information
This press release contains non-GAAP financial measures, including non-GAAP earnings and related EPS information, that are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods including restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges in connection with the acquisition or licensing of third party intellectual property rights, divestiture and equity investment gains or losses, upfront payments from out-licensed assets, pension charges, legal and other contractual settlements and debt redemption gains or losses, among other items.
5
Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information is an indication of our baseline performance before items that are considered by us to not be reflective of our ongoing results. In addition, this information is among the primary indicators we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP.
Statement on Cautionary Factors
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to successfully execute its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
6
Company and Conference Call Information
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
There will be a conference call on July 26, 2018 at 10:30 a.m. EDT during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by calling the U.S. toll free 866-548-4713 or international 323-794-2093, confirmation code: 4235170. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on July 26, 2018 through 1:30 p.m. EDT on August 9, 2018. The replay will also be available through http://investor.bms.com or by calling the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 4235170.
For more information, contact:
Communications: Lisa McCormick Lavery, 609-252-7602, lisa.mccormicklavery@bms.com
Investor Relations: John Elicker, 609-252-4611, john.elicker@bms.com, Tim Power, 609-252-7509, timothy.power@bms.com or Bill Szablewski, 609-252-5894, william.szablewski@bms.com.
7
BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUE
FOR THE THREE MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
Worldwide Revenues | U.S. Revenues | |||||||||||||||||||||
2018 | 2017 | % Change | 2018 | 2017 | % Change | |||||||||||||||||
Three Months Ended June 30, | ||||||||||||||||||||||
Prioritized Brands | ||||||||||||||||||||||
Opdivo | $ | 1,627 | $ | 1,195 | 36 | % | $ | 1,024 | $ | 768 | 33 | % | ||||||||||
Eliquis | 1,650 | 1,176 | 40 | % | 979 | 703 | 39 | % | ||||||||||||||
Orencia | 711 | 650 | 9 | % | 501 | 449 | 12 | % | ||||||||||||||
Sprycel | 535 | 506 | 6 | % | 310 | 281 | 10 | % | ||||||||||||||
Yervoy | 315 | 322 | (2 | )% | 228 | 245 | (7 | )% | ||||||||||||||
Empliciti | 64 | 55 | 16 | % | 41 | 37 | 11 | % | ||||||||||||||
Established Brands | ||||||||||||||||||||||
Baraclude | 179 | 273 | (34 | )% | 9 | 12 | (25 | )% | ||||||||||||||
Sustiva Franchise | 73 | 188 | (61 | )% | 8 | 161 | (95 | )% | ||||||||||||||
Reyataz Franchise | 117 | 188 | (38 | )% | 54 | 87 | (38 | )% | ||||||||||||||
Hepatitis C Franchise | 12 | 112 | (89 | )% | (2 | ) | 30 | ** | ||||||||||||||
Other Brands | 421 | 479 | (12 | )% | 78 | 92 | (15 | )% | ||||||||||||||
Total | $ | 5,704 | $ | 5,144 | 11 | % | $ | 3,230 | $ | 2,865 | 13 | % | ||||||||||
8
BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUE
FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
Worldwide Revenues | U.S. Revenues | |||||||||||||||||||||
2018 | 2017 | % Change | 2018 | 2017 | % Change | |||||||||||||||||
Six Months Ended June 30, | ||||||||||||||||||||||
Prioritized Brands | ||||||||||||||||||||||
Opdivo | $ | 3,138 | $ | 2,322 | 35 | % | $ | 1,962 | $ | 1,529 | 28 | % | ||||||||||
Eliquis | 3,156 | 2,277 | 39 | % | 1,864 | 1,402 | 33 | % | ||||||||||||||
Orencia | 1,304 | 1,185 | 10 | % | 886 | 811 | 9 | % | ||||||||||||||
Sprycel | 973 | 969 | — | 524 | 528 | (1 | )% | |||||||||||||||
Yervoy | 564 | 652 | (13 | )% | 390 | 488 | (20 | )% | ||||||||||||||
Empliciti | 119 | 108 | 10 | % | 78 | 73 | 7 | % | ||||||||||||||
Established Brands | ||||||||||||||||||||||
Baraclude | 404 | 555 | (27 | )% | 19 | 26 | (27 | )% | ||||||||||||||
Sustiva Franchise | 157 | 372 | (58 | )% | 18 | 314 | (94 | )% | ||||||||||||||
Reyataz Franchise | 241 | 381 | (37 | )% | 105 | 175 | (40 | )% | ||||||||||||||
Hepatitis C Franchise | 15 | 274 | (95 | )% | 3 | 72 | (96 | )% | ||||||||||||||
Other Brands | 826 | 978 | (16 | )% | 159 | 185 | (14 | )% | ||||||||||||||
Total | $ | 10,897 | $ | 10,073 | 8 | % | $ | 6,008 | $ | 5,603 | 7 | % | ||||||||||
9
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars and shares in millions except per share data)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||||||
Net product sales | $ | 5,461 | $ | 4,770 | $ | 10,433 | $ | 9,350 | ||||||||
Alliance and other revenues | 243 | 374 | 464 | 723 | ||||||||||||
Total Revenues | 5,704 | 5,144 | 10,897 | 10,073 | ||||||||||||
Cost of products sold | 1,625 | 1,569 | 3,209 | 2,834 | ||||||||||||
Marketing, selling and administrative | 1,131 | 1,187 | 2,111 | 2,272 | ||||||||||||
Research and development | 2,435 | 1,679 | 3,685 | 2,982 | ||||||||||||
Other income (net) | (4 | ) | (586 | ) | (404 | ) | (1,265 | ) | ||||||||
Total Expenses | 5,187 | 3,849 | 8,601 | 6,823 | ||||||||||||
Earnings Before Income Taxes | 517 | 1,295 | 2,296 | 3,250 | ||||||||||||
Provision for Income Taxes | 135 | 373 | 419 | 802 | ||||||||||||
Net Earnings | 382 | 922 | 1,877 | 2,448 | ||||||||||||
Net Earnings/(Loss) Attributable to Noncontrolling Interest | 9 | 6 | 18 | (42 | ) | |||||||||||
Net Earnings Attributable to BMS | $ | 373 | $ | 916 | $ | 1,859 | $ | 2,490 | ||||||||
Average Common Shares Outstanding: | ||||||||||||||||
Basic | 1,633 | 1,644 | 1,633 | 1,653 | ||||||||||||
Diluted | 1,636 | 1,650 | 1,638 | 1,660 | ||||||||||||
Earnings per Common Share | ||||||||||||||||
Basic | $ | 0.23 | $ | 0.56 | $ | 1.14 | $ | 1.51 | ||||||||
Diluted | 0.23 | 0.56 | 1.13 | 1.50 | ||||||||||||
Other income (net) | ||||||||||||||||
Interest expense | $ | 45 | $ | 52 | $ | 91 | $ | 97 | ||||||||
Investment income | (38 | ) | (29 | ) | (74 | ) | (55 | ) | ||||||||
Loss/(gain) on equity investments | 356 | (5 | ) | 341 | (12 | ) | ||||||||||
Provision for restructuring | 37 | 15 | 57 | 179 | ||||||||||||
Litigation and other settlements | (1 | ) | (5 | ) | (1 | ) | (489 | ) | ||||||||
Equity in net income of affiliates | (27 | ) | (20 | ) | (51 | ) | (38 | ) | ||||||||
Divestiture gains | (25 | ) | — | (70 | ) | (127 | ) | |||||||||
Royalties and licensing income | (353 | ) | (685 | ) | (720 | ) | (884 | ) | ||||||||
Transition and other service fees | (1 | ) | (13 | ) | (5 | ) | (20 | ) | ||||||||
Pension and postretirement | (19 | ) | (11 | ) | (30 | ) | (10 | ) | ||||||||
Intangible asset impairment | — | — | 64 | — | ||||||||||||
Loss on debt redemption | — | 109 | — | 109 | ||||||||||||
Other | 22 | 6 | (6 | ) | (15 | ) | ||||||||||
Other income (net) | $ | (4 | ) | $ | (586 | ) | $ | (404 | ) | $ | (1,265 | ) | ||||
10
BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||||||
Impairment charges | $ | — | $ | 127 | $ | 10 | $ | 127 | ||||||||
Accelerated depreciation and other shutdown costs | 14 | 3 | 17 | 3 | ||||||||||||
Cost of products sold | 14 | 130 | 27 | 130 | ||||||||||||
Marketing, selling and administrative | — | — | 1 | — | ||||||||||||
License and asset acquisition charges | 1,075 | 393 | 1,135 | 443 | ||||||||||||
IPRD impairments | — | — | — | 75 | ||||||||||||
Site exit costs and other | 19 | 96 | 39 | 168 | ||||||||||||
Research and development | 1,094 | 489 | 1,174 | 686 | ||||||||||||
Loss/(gain) on equity investments | 356 | — | 341 | — | ||||||||||||
Provision for restructuring | 37 | 15 | 57 | 179 | ||||||||||||
Litigation and other settlements | — | — | — | (481 | ) | |||||||||||
Divestiture gains | (25 | ) | — | (68 | ) | (100 | ) | |||||||||
Royalties and licensing income | (25 | ) | (497 | ) | (75 | ) | (497 | ) | ||||||||
Pension and postretirement | 37 | 36 | 68 | 69 | ||||||||||||
Intangible asset impairment | — | — | 64 | — | ||||||||||||
Loss on debt redemption | — | 109 | — | 109 | ||||||||||||
Other income (net) | 380 | (337 | ) | 387 | (721 | ) | ||||||||||
Increase to pretax income | 1,488 | 282 | 1,589 | 95 | ||||||||||||
Income taxes on specified items | (218 | ) | 20 | (226 | ) | 92 | ||||||||||
Income taxes attributed to U.S. tax reform | 3 | — | (29 | ) | — | |||||||||||
Income taxes | (215 | ) | 20 | (255 | ) | 92 | ||||||||||
Increase to net earnings | 1,273 | 302 | 1,334 | 187 | ||||||||||||
Noncontrolling interest | — | — | — | (59 | ) | |||||||||||
Increase to net earnings used for diluted Non-GAAP EPS calculation | $ | 1,273 | $ | 302 | $ | 1,334 | $ | 128 | ||||||||
11
BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
Three Months Ended June 30, 2018 | Six Months Ended June 30, 2018 | ||||||||||||||||||||||
GAAP | Specified Items(a) | Non- GAAP | GAAP | Specified Items(a) | Non- GAAP | ||||||||||||||||||
Gross Profit | $ | 4,079 | $ | 14 | $ | 4,093 | $ | 7,688 | $ | 27 | $ | 7,715 | |||||||||||
Marketing, selling and administrative | 1,131 | — | 1,131 | 2,111 | (1 | ) | 2,110 | ||||||||||||||||
Research and development | 2,435 | (1,094 | ) | 1,341 | 3,685 | (1,174 | ) | 2,511 | |||||||||||||||
Other income (net) | (4 | ) | (380 | ) | (384 | ) | (404 | ) | (387 | ) | (791 | ) | |||||||||||
Earnings Before Income Taxes | 517 | 1,488 | 2,005 | 2,296 | 1,589 | 3,885 | |||||||||||||||||
Provision for Income Taxes | 135 | (215 | ) | 350 | 419 | (255 | ) | 674 | |||||||||||||||
Noncontrolling interest | 9 | — | 9 | 18 | — | 18 | |||||||||||||||||
Net Earnings Attributable to BMS used for Diluted EPS Calculation | $ | 373 | $ | 1,273 | $ | 1,646 | $ | 1,859 | $ | 1,334 | $ | 3,193 | |||||||||||
Average Common Shares Outstanding - Diluted | 1,636 | 1,636 | 1,636 | 1,638 | 1,638 | 1,638 | |||||||||||||||||
Diluted Earnings Per Share | $ | 0.23 | $ | 0.78 | $ | 1.01 | $ | 1.13 | $ | 0.82 | $ | 1.95 | |||||||||||
Effective Tax Rate | 26.1 | % | (8.6 | )% | 17.5 | % | 18.2 | % | (0.9 | )% | 17.3 | % | |||||||||||
Three Months Ended June 30, 2017 | Six Months Ended June 30, 2017 | ||||||||||||||||||||||
GAAP | Specified Items(a) | Non- GAAP | GAAP | Specified Items(a) | Non- GAAP | ||||||||||||||||||
Gross Profit | $ | 3,575 | $ | 130 | $ | 3,705 | $ | 7,239 | $ | 130 | $ | 7,369 | |||||||||||
Marketing, selling and administrative | 1,187 | — | 1,187 | 2,272 | — | 2,272 | |||||||||||||||||
Research and development | 1,679 | (489 | ) | 1,190 | 2,982 | (686 | ) | 2,296 | |||||||||||||||
Other income (net) | (586 | ) | 337 | (249 | ) | (1,265 | ) | 721 | (544 | ) | |||||||||||||
Earnings Before Income Taxes | 1,295 | 282 | 1,577 | 3,250 | 95 | 3,345 | |||||||||||||||||
Provision for Income Taxes | 373 | 20 | 353 | 802 | 92 | 710 | |||||||||||||||||
Noncontrolling interest | 6 | — | 6 | (42 | ) | (59 | ) | 17 | |||||||||||||||
Net Earnings Attributable to BMS used for Diluted EPS Calculation | $ | 916 | $ | 302 | $ | 1,218 | $ | 2,490 | $ | 128 | $ | 2,618 | |||||||||||
Average Common Shares Outstanding - Diluted | 1,650 | 1,650 | 1,650 | 1,660 | 1,660 | 1,660 | |||||||||||||||||
Diluted Earnings Per Share | $ | 0.56 | $ | 0.18 | $ | 0.74 | $ | 1.50 | $ | 0.08 | $ | 1.58 | |||||||||||
Effective Tax Rate | 28.8 | % | (6.4 | )% | 22.4 | % | 24.7 | % | (3.5 | )% | 21.2 | % | |||||||||||
(a) | Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate. | |||
12
BRISTOL-MYERS SQUIBB COMPANY
NET CASH/(DEBT) CALCULATION
AS OF JUNE 30, 2018 AND MARCH 31, 2018
(Unaudited, dollars in millions)
June 30, 2018 | March 31, 2018 | |||||||
Cash and cash equivalents | $ | 4,999 | $ | 5,342 | ||||
Marketable securities - current | 1,076 | 1,428 | ||||||
Marketable securities - non-current | 2,117 | 2,252 | ||||||
Cash, cash equivalents and marketable securities | 8,192 | 9,022 | ||||||
Short-term debt obligations | (1,716 | ) | (1,925 | ) | ||||
Long-term debt | (5,671 | ) | (5,775 | ) | ||||
Net cash position | $ | 805 | $ | 1,322 | ||||
13